IBDEI1KL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25092,1,3,0)
 ;;=3^Herpesviral Vesicular Dermatitis
 ;;^UTILITY(U,$J,358.3,25092,1,4,0)
 ;;=4^B00.1
 ;;^UTILITY(U,$J,358.3,25092,2)
 ;;=^5000468
 ;;^UTILITY(U,$J,358.3,25093,0)
 ;;=B97.89^^107^1213^89
 ;;^UTILITY(U,$J,358.3,25093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25093,1,3,0)
 ;;=3^Viral Agent Cause of Disease
 ;;^UTILITY(U,$J,358.3,25093,1,4,0)
 ;;=4^B97.89
 ;;^UTILITY(U,$J,358.3,25093,2)
 ;;=^5000879
 ;;^UTILITY(U,$J,358.3,25094,0)
 ;;=B97.10^^107^1213^21
 ;;^UTILITY(U,$J,358.3,25094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25094,1,3,0)
 ;;=3^Enterovirus Cause of Disease
 ;;^UTILITY(U,$J,358.3,25094,1,4,0)
 ;;=4^B97.10
 ;;^UTILITY(U,$J,358.3,25094,2)
 ;;=^5000861
 ;;^UTILITY(U,$J,358.3,25095,0)
 ;;=B34.9^^107^1213^90
 ;;^UTILITY(U,$J,358.3,25095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25095,1,3,0)
 ;;=3^Viral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,25095,1,4,0)
 ;;=4^B34.9
 ;;^UTILITY(U,$J,358.3,25095,2)
 ;;=^5000603
 ;;^UTILITY(U,$J,358.3,25096,0)
 ;;=A69.20^^107^1213^50
 ;;^UTILITY(U,$J,358.3,25096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25096,1,3,0)
 ;;=3^Lyme Disease,Unspec
 ;;^UTILITY(U,$J,358.3,25096,1,4,0)
 ;;=4^A69.20
 ;;^UTILITY(U,$J,358.3,25096,2)
 ;;=^5000375
 ;;^UTILITY(U,$J,358.3,25097,0)
 ;;=A69.22^^107^1213^52
 ;;^UTILITY(U,$J,358.3,25097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25097,1,3,0)
 ;;=3^Neurologic Disorders d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,25097,1,4,0)
 ;;=4^A69.22
 ;;^UTILITY(U,$J,358.3,25097,2)
 ;;=^5000377
 ;;^UTILITY(U,$J,358.3,25098,0)
 ;;=A69.21^^107^1213^51
 ;;^UTILITY(U,$J,358.3,25098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25098,1,3,0)
 ;;=3^Meningitis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,25098,1,4,0)
 ;;=4^A69.21
 ;;^UTILITY(U,$J,358.3,25098,2)
 ;;=^5000376
 ;;^UTILITY(U,$J,358.3,25099,0)
 ;;=A69.29^^107^1213^18
 ;;^UTILITY(U,$J,358.3,25099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25099,1,3,0)
 ;;=3^Conditions d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,25099,1,4,0)
 ;;=4^A69.29
 ;;^UTILITY(U,$J,358.3,25099,2)
 ;;=^5000379
 ;;^UTILITY(U,$J,358.3,25100,0)
 ;;=A69.23^^107^1213^5
 ;;^UTILITY(U,$J,358.3,25100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25100,1,3,0)
 ;;=3^Arthritis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,25100,1,4,0)
 ;;=4^A69.23
 ;;^UTILITY(U,$J,358.3,25100,2)
 ;;=^5000378
 ;;^UTILITY(U,$J,358.3,25101,0)
 ;;=A51.0^^107^1213^29
 ;;^UTILITY(U,$J,358.3,25101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25101,1,3,0)
 ;;=3^Genital Syphilis,Primary
 ;;^UTILITY(U,$J,358.3,25101,1,4,0)
 ;;=4^A51.0
 ;;^UTILITY(U,$J,358.3,25101,2)
 ;;=^5000272
 ;;^UTILITY(U,$J,358.3,25102,0)
 ;;=A52.3^^107^1213^54
 ;;^UTILITY(U,$J,358.3,25102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25102,1,3,0)
 ;;=3^Neurosyphilis,Unspec
 ;;^UTILITY(U,$J,358.3,25102,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,25102,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,25103,0)
 ;;=A52.10^^107^1213^53
 ;;^UTILITY(U,$J,358.3,25103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25103,1,3,0)
 ;;=3^Neurosyphilis Symptomatic,Unspec
 ;;^UTILITY(U,$J,358.3,25103,1,4,0)
 ;;=4^A52.10
 ;;^UTILITY(U,$J,358.3,25103,2)
 ;;=^5000291
 ;;^UTILITY(U,$J,358.3,25104,0)
 ;;=A52.9^^107^1213^49
 ;;^UTILITY(U,$J,358.3,25104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25104,1,3,0)
 ;;=3^Late Syphilis,Unspec
 ;;^UTILITY(U,$J,358.3,25104,1,4,0)
 ;;=4^A52.9
